Bristol Myers Squibb announced it is purchasing the first Nvidia DGX SuperPOD built on the Vera Rubin architecture to accelerate AI-powered drug discovery and development, marking a milestone in life sciences AI infrastructure.

1 min read

Bristol Myers Squibb Buys Nvidia DGX SuperPOD for Drug Discovery

Bristol Myers Squibb Buys Nvidia DGX SuperPOD for Drug Discovery

FAQ

What is Nvidia's DGX SuperPOD?

It's an integrated supercomputing system designed for large-scale AI workloads, based on the new Vera Rubin architecture.

How will Bristol Myers Squibb use this system?

It will use the system to accelerate drug discovery and development by analyzing large datasets and training AI models.

Is this deal relevant for the MENA region?

Yes, it highlights the global trend of AI in pharma, encouraging regional companies to adopt similar technologies.

Source: Artificial Intelligence News

AI-assisted content, human-reviewed.